T. Rowe Price Associates’s Veradermics Inc MANE Stock Holding History

T. Rowe Price Associates’s Portfolio MANE Stock Details MANE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Buy	+18,114	New	+$1.7M	﹤0.01%	1952

Other funds holding MANE

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

T. Rowe Price Associates's MANE Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Veradermics Inc (MANE) in Q2 2026: 18,114 shares worth $2.23M. The stake represents ﹤0.01% of the portfolio and ranks #1952 among its holdings.

148 funds tracked by Wall St. Rank hold MANE as of Q2 2026.

T. Rowe Price Associates held 18,114 shares of Veradermics Inc worth $2.23M as of Q2 2026.
Veradermics Inc was a new T. Rowe Price Associates position in Q2 2026.
Veradermics Inc made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1952 holding.
148 funds tracked by Wall St. Rank held Veradermics Inc as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.